EUROPAD

Conference report Europad 2026

Europad 17 - Bucharest May, 29-31 2026

The 17th Europad congress took place in Bucharest (Romania) last May, 29-31 as planned.

 

Abstracts

Download the abstracts of EUROPAD 2026 (PDF)

 

Posters

Reproductive health in addiction

Reproductive health in addiction

Agata Mikolajkow, National Drug Treatment Centre, Dublin, Ireland

Characteristics of retention and survival of lifetime pathological gambling in methadone maintenance treatment

Characteristics of retention and survival of lifetime pathological gambling in methadone maintenance treatment

Miriam & Sheldon G. Adelson Clinic for Drug Abuse Treatment & Research, Tel-Aviv Sourasky University Medical Center & Faculty of Medical & Health Sciences , Tel Aviv University Anat Sason, Shaul Schreiber, Einat Peles, Miriam Adelson

Individualised dosing of long-acting injectable buprenorphine (CAM2038) in Phase 3 studies

Individualised dosing of long-acting injectable buprenorphine (CAM2038) in Phase 3 studies

Nicholas Lintzeris, Genie L. Bailey, Adrian J. Dunlop, Edward V. Nunes, Michael P. Frost, Stefan Peterson, Peter Almgren, Susanna Meyner, Elin Banke Nordbeck, Natalie Budilovsky-Kelley

Buprenorphine maintenance treatment in a community addiction service in Barcelona: clinical characteristics and outcomes of oral and long-acting subcutaneous formulations

Buprenorphine maintenance treatment in a community addiction service in Barcelona: clinical characteristics and outcomes of oral and long-acting subcutaneous formulations

Josep MAYANS HENARES, Juan José FUENTES VALENZUELA, José María GINÉS MIRANDA, Paula MOLLA ROIG, Judith REBOLLO GELABERT, Mariona EMILIO ROVIRA, Albert ROQUER GRAU, Silvia MARTÍNEZ LÓPEZ, Ariana GELON TOMÁS, Alejandro ALCÁNTARA SEGARRA, Alba LLIMONA GONZÁLEZ, Gerard Angel MATEU CODINA, Maria Francina FONSECA CASALS

Real-world impact of depot buprenorphine on quality of life among patients in opioid agonist treatment: Findings from the ARIDE Study

Real-world impact of depot buprenorphine on quality of life among patients in opioid agonist treatment: Findings from the ARIDE Study

Jens Reimer, Uwe Verthein, Bernd Schulte

ENCOCOS+ project: Neuropsychological evaluation on car-driving and Opiate Use Disorder Patients.

ENCOCOS+ project: Neuropsychological evaluation on car-driving and Opiate Use Disorder Patients.

Carlos Roncero, Pilar González-Peláez, Milton Merizalde-Torres, Sol Cobo, Alicia Fernández-Parra, Enrique Poza, María Sanz-Esteban, Ana Beltrán, María Luisa Poladura, Armando González-Sánchez

Changes in opioid agonist treatment in Stockholm, 2022–2026: a register-based study of long-acting injectable buprenorphine (LAIB)

Changes in opioid agonist treatment in Stockholm, 2022–2026: a register-based study of long-acting injectable buprenorphine (LAIB)

Thunberg M, Widing H, Kåberg M

 

Video
Adverse Childhood Experiences in Buprenorphine treatment
Adverse Childhood Experiences in Buprenorphine treatment

Author: ERIN WINSTANLEY
Session: Room A

Childhood Trauma and OMT Retention and Relapse
Childhood Trauma and OMT Retention and Relapse

Author: ADRIAN ABAGIU
Session: Room A

Key Elements and Lessons Learned
Key Elements and Lessons Learned

Author: DACE SVIKIS
Session: Room A

Toward a Harmonized, Pragmatic Framework for Evaluating Pharmacological Treatments in Alcohol Use Disorder: A Multicenter European Proposal
Toward a Harmonized, Pragmatic Framework for Evaluating Pharmacological Treatments in Alcohol Use Disorder: A Multicenter European Proposal

Author: FILIPPO DELLA ROCCA
Session: Room A

Opioid Antagonist and Anti-Psychotic Partial Agonists Treatment on Patients with Alcohol Use Disorders in a Community Mental Health Treatment in Portugal
Opioid Antagonist and Anti-Psychotic Partial Agonists Treatment on Patients with Alcohol Use Disorders in a Community Mental Health Treatment in Portugal

Author: CELIA FRANCO
Session: Room A

Alcohol Use in Opioid Agonist Therapy Patients: The Role of Inadequate Dosing and Treatment Compliance
Alcohol Use in Opioid Agonist Therapy Patients: The Role of Inadequate Dosing and Treatment Compliance

Author: LILJANA IGNJATOVA
Session: Room A

INTAUD - How Can We Improve the Treatment of AUD Patients?
INTAUD - How Can We Improve the Treatment of AUD Patients?

Author: ALBRECHT ULMER
Session: Room A

Smoking in Opioid Use Disorder: An Ubiquitous but Neglected Determinant of Morbidity and Mortality
Smoking in Opioid Use Disorder: An Ubiquitous but Neglected Determinant of Morbidity and Mortality

Author: PETER HAJEK
Session: Room A

Nicotine, Dependence and Addiction: Neurobiological and Behavioural Distinctions in Patients with Substance Use Disorders
Nicotine, Dependence and Addiction: Neurobiological and Behavioural Distinctions in Patients with Substance Use Disorders

Author: ANGELO GIOVANNI ICRO MAREMMANI
Session: Room A

Harm Reduction Strategies for Smoking in Opioid-Treated Patients: Clinical Evidence and Practical Approaches
Harm Reduction Strategies for Smoking in Opioid-Treated Patients: Clinical Evidence and Practical Approaches

Author: SHARON COX
Session: Room A

Progress and challenge to opioid treatment in the United States
Progress and challenge to opioid treatment in the United States

Author: MARK PARRINO
Session: Room A

Tobacco Use Disorder through the dual disorders model: State of the art
Tobacco Use Disorder through the dual disorders model: State of the art

Author: NESTOR SZERMAN
Session: Room A

Medicinal Cannabis in the treatment of substance use disorders and comorbid conditions
Medicinal Cannabis in the treatment of substance use disorders and comorbid conditions

Author: NICHOLAS LINTZERIS
Session: Room A

Stimulants in the treatment of substance use and comorbid disorders
Stimulants in the treatment of substance use and comorbid disorders

Author: WIM VAN DEN BRINK
Session: Room A

Understanding the Opioid Overdose Epidemics in USA
Understanding the Opioid Overdose Epidemics in USA

Author: DIPALI RINKER
Session: Room A

Understanding Contrasts and Challenges of Opioid Epidemics USA vs Europe
Understanding Contrasts and Challenges of Opioid Epidemics USA vs Europe

Author: MERCEDES LOVRECIC
Session: Room A

Are we doing the right things, the right way? Medication Assisted Treatment for Opioid Use Disorder in the Netherlands
Are we doing the right things, the right way? Medication Assisted Treatment for Opioid Use Disorder in the Netherlands

Author: PETER VOSSENBERG
Session: Room A

Opiate Use Disorder and Suicide: The Relevance of Dual Disorders
Opiate Use Disorder and Suicide: The Relevance of Dual Disorders

Author: CARLOS ALONSO RONCERO
Session: Room A

The role of medicinal cannabis in treating common comorbidities in patients with opioid use disorder - most commonly chronic pain, mental health conditions (e.g. anxiety, PTSD) and sleep conditions
The role of medicinal cannabis in treating common comorbidities in patients with opioid use disorder - most commonly chronic pain, mental health conditions (e.g. anxiety, PTSD) and sleep conditions

Author: LAILA PARVARESH
Session: Room A

The role of medicinal cannabis in treatment of comorbid substance use disorders - including cannabis use disorder and alcohol use disorder, and opioid withdrawal
The role of medicinal cannabis in treatment of comorbid substance use disorders - including cannabis use disorder and alcohol use disorder, and opioid withdrawal

Author: NICHOLAS LINTZERIS
Session: Room A

Do we use opioid medications properly to achieve the best possible therapeutic response? Lessons from observational studies and real-world data
Do we use opioid medications properly to achieve the best possible therapeutic response? Lessons from observational studies and real-world data

Author: MAURICE DEMATTEIS
Session: Room A

Mood Disorders in Heroin Addiction – Clinical Challenges and Treatment Perspectives
Mood Disorders in Heroin Addiction – Clinical Challenges and Treatment Perspectives

Author: ANGELO GIOVANNI ICRO MAREMMANI
Session: Room A

How do we Reduce Barriers to OAT? Barriers to OAT? From Low-Threshold Starts to Long-Term Support
How do we Reduce Barriers to OAT? Barriers to OAT? From Low-Threshold Starts to Long-Term Support

Author: MARTIN KABERG,SARAH DONALDSON
Session: Room A

Methadone Use in United States: Practices, Policies, and Perceptions
Methadone Use in United States: Practices, Policies, and Perceptions

Author: GIANLUCA DE LEO
Session: Room A

Innovative Entrepreneurial Approaches to Recovery among Economically Disadvantaged Groups
Innovative Entrepreneurial Approaches to Recovery among Economically Disadvantaged Groups

Author: VAHÉ HEBOYAN
Session: Room A

Evidence-Based Strategies for Maternal Substance Use Care in Rural Settings
Evidence-Based Strategies for Maternal Substance Use Care in Rural Settings

Author: MARLO VERNON
Session: Room A

Managing opioid addiction: lessons learned that shouldn’t be forgotten
Managing opioid addiction: lessons learned that shouldn’t be forgotten

Author: MARTA TORRENS
Session: Room A

Opioid addiction, anxiety,depression, sleep and outcome in treatment: how much is the craving experience meaningful?
Opioid addiction, anxiety,depression, sleep and outcome in treatment: how much is the craving experience meaningful?

Author: MARC AURIACOMBE
Session: Room A

Exploring the Biopsychosocial Needs of Ageing Persons with a Heroin Use Disorder in Treatment in Malta
Exploring the Biopsychosocial Needs of Ageing Persons with a Heroin Use Disorder in Treatment in Malta

Author: ANNA MARIA VELLA
Session: Room A

The Emerging Issue of Pharmaceutical Opiates of Abuse in Italy
The Emerging Issue of Pharmaceutical Opiates of Abuse in Italy

Author: MATTEO PACINI
Session: Room A

The Challenge of Iatrogenic Opioid Addiction: A Six-Year Retrospective Analysis in an Italian Addiction Service
The Challenge of Iatrogenic Opioid Addiction: A Six-Year Retrospective Analysis in an Italian Addiction Service

Author: SARAH VECCHIO
Session: Room A

Pharmacokinetics and Pharmacodynamics of Intranasal Diacetylmorphine in Heroin-Assisted Treatment
Pharmacokinetics and Pharmacodynamics of Intranasal Diacetylmorphine in Heroin-Assisted Treatment

Author: ADRIAN GUESSOUM
Session: Room A

Side Effects of Opioid Agonists - a Cross- Sectional Survey Study
Side Effects of Opioid Agonists - a Cross- Sectional Survey Study

Author: MARC VOGEL
Session: Room A

ADHD and Substance Use Disorder
ADHD and Substance Use Disorder

Author: GABRIELE FISCHER
Session: Room A

ARAS integrated services for PWIUD
ARAS integrated services for PWIUD

Author: MONICA DAN
Session: Room A

Mobile harm reduction, treatment and rehabilitation services for PWIUD
Mobile harm reduction, treatment and rehabilitation services for PWIUD

Author: ANDREJ KASTELIC
Session: Room A

Psychosocial and medical rehabilitation mobile service for people with dual disorders
Psychosocial and medical rehabilitation mobile service for people with dual disorders

Author: NUSA SEGREC
Session: Room A

The Role of Powdered Methadone Formulations in Optimising Opioid Agonist Treatment
The Role of Powdered Methadone Formulations in Optimising Opioid Agonist Treatment

Author: LORENZO SOMAINI
Session: Room A

Treatment of addictive disorders: Integration into mainstream health care
Treatment of addictive disorders: Integration into mainstream health care

Author: EMILIS SUBATA
Session: Room A

Implementing Long-Acting Injectable Treatments for Opioid Use Disorder: A Multilevel Stigma Perspective
Implementing Long-Acting Injectable Treatments for Opioid Use Disorder: A Multilevel Stigma Perspective

Author: DIPALI RINKER
Session: Room B

Implementation of Long-Acting Injectable Buprenorphine in a Needle and Syringe Program: A Clinical Pilot Study of Access and Retention in Treatment
Implementation of Long-Acting Injectable Buprenorphine in a Needle and Syringe Program: A Clinical Pilot Study of Access and Retention in Treatment

Author: MARTIN KÅBERG
Session: Room B

Retention in Long-Acting Buprenorphine Treatment
Retention in Long-Acting Buprenorphine Treatment

Author: CHLOÉ POUPAUD
Session: Room B

Retention and Other Efficacy Outcomes with Long-Acting Injectable Buprenorphine (Buvidal®) in France: A National Retrospective Cross-Sectional Study (Opale 2)
Retention and Other Efficacy Outcomes with Long-Acting Injectable Buprenorphine (Buvidal®) in France: A National Retrospective Cross-Sectional Study (Opale 2)

Author: ALICE DESCHENAU
Session: Room B

GLP-1 Receptor Agonists as Emerging Therapeutics not Only for Opioid Use Disorders
GLP-1 Receptor Agonists as Emerging Therapeutics not Only for Opioid Use Disorders

Author: ROBERTO CICCOCIOPPO
Session: Room B

Optimizing the Transition to Long-Acting Buprenorphine: Clinical Insights and Patient Perspectives to Improve Real-World Practice
Optimizing the Transition to Long-Acting Buprenorphine: Clinical Insights and Patient Perspectives to Improve Real-World Practice

Author: JULIEN CABÉ
Session: Room B

Withdrawal of Opioid Analgesics after Unsuccessful Gradual Tapering in Chronic Non-Cancer Pain: Results from the SEVROP Study
Withdrawal of Opioid Analgesics after Unsuccessful Gradual Tapering in Chronic Non-Cancer Pain: Results from the SEVROP Study

Author: CÉLIAN BERTIN
Session: Room B

Opioid Analgesics: Management Considerations
Opioid Analgesics: Management Considerations

Author: MATHIEU CHAPPUY
Session: Room B

Narcissism and Substance Use Disorder. The Importance of Self-Transcendence in “Spontaneous Remission.”
Narcissism and Substance Use Disorder. The Importance of Self-Transcendence in “Spontaneous Remission.”

Author: CHRISTOPHER WURM
Session: Room B

Trauma History Among Patients Receiving Methadone Maintenance Treatment: Sex Differences, Characteristics, and Outcomes
Trauma History Among Patients Receiving Methadone Maintenance Treatment: Sex Differences, Characteristics, and Outcomes

Author: EINAT PELES
Session: Room B

Why Do Patients Respond Differently to Opioid Agonist Treatment? Evidence from Data
Why Do Patients Respond Differently to Opioid Agonist Treatment? Evidence from Data

Author: LILJANA IGNJATOVA
Session: Room B

Levomethadone Selectively Reduces Emotional Impulsivity in ASRS-Positive ADHD–OUD Patients, Independent of Dose Escalation
Levomethadone Selectively Reduces Emotional Impulsivity in ASRS-Positive ADHD–OUD Patients, Independent of Dose Escalation

Author: ALESSANDRO PALLUCCHINI
Session: Room B

Long-Acting Opioid Agonists and Quality of Life in the Treatment of OUD
Long-Acting Opioid Agonists and Quality of Life in the Treatment of OUD

Author: LORENZO SOMAINI
Session: Room B

Motivational interventions in Methadone Maintenance Treatment
Motivational interventions in Methadone Maintenance Treatment

Author: RIK BES
Session: Room B

Addiction Prevention – a Different Perspective, a Different Concept
Addiction Prevention – a Different Perspective, a Different Concept

Author: ALBRECHT ULMER
Session: Room B

Should Off-Label Prescription of Controlled Medicines Be Notified? The Implementation of the Swiss Narcotics Act
Should Off-Label Prescription of Controlled Medicines Be Notified? The Implementation of the Swiss Narcotics Act

Author: OLIVIER SIMON
Session: Room B

Between Voluntary and Compulsory Care: Ethical and Clinical Dilemmas in Treating Adolescents with Opioid and Other Substance Use Disorders
Between Voluntary and Compulsory Care: Ethical and Clinical Dilemmas in Treating Adolescents with Opioid and Other Substance Use Disorders

Author: IVONA KRULJAC
Session: Room B

 

Conference photo gallery
  • EUROPAD 2026 - Bucarest conference
  • EUROPAD 2026 - Bucarest conference
  • EUROPAD 2026 - Bucarest conference
  • EUROPAD 2026 - Bucarest conference
  • EUROPAD 2026 - Bucarest conference
  • EUROPAD 2026 - Bucarest conference
  • EUROPAD 2026 - Bucarest conference
  • EUROPAD 2026 - Bucarest conference
  • EUROPAD 2026 - Bucarest conference
  • EUROPAD 2026 - Bucarest conference
  • EUROPAD 2026 - Bucarest conference
  • EUROPAD 2026 - Bucarest conference
  • EUROPAD 2026 - Bucarest conference
  • EUROPAD 2026 - Bucarest conference
  • EUROPAD 2026 - Bucarest conference
  • EUROPAD 2026 - Bucarest conference
  • EUROPAD 2026 - Bucarest conference
  • EUROPAD 2026 - Bucarest conference
  • EUROPAD 2026 - Bucarest conference
  • EUROPAD 2026 - Bucarest conference
  • EUROPAD 2026 - Bucarest conference

 

Chimera Award Recipients
  • Chimera Award 2026 - CHRISTOPHER B. CHAPLEO (Redbourne, Gainsborough, Lincolnshire, UK)
    CHRISTOPHER B. CHAPLEO (Redbourne, Gainsborough, Lincolnshire, UK)
  • Chimera Award 2026 - CHRISTOPHER B. CHAPLEO (Redbourne, Gainsborough, Lincolnshire, UK)
    CHRISTOPHER B. CHAPLEO (Redbourne, Gainsborough, Lincolnshire, UK)
  • Chimera Award 2026 - EMILIS SUBATA (Vilnius, Lithuania, EU)
    EMILIS SUBATA (Vilnius, Lithuania, EU)
  • Chimera Award 2026 - EMILIS SUBATA (Vilnius, Lithuania, EU)
    EMILIS SUBATA (Vilnius, Lithuania, EU)
  • Chimera Award 2026 - NESTOR SZERMAN (Madrid, Spain, EU)
    NESTOR SZERMAN (Madrid, Spain, EU)
  • Chimera Award 2026 - NESTOR SZERMAN (Madrid, Spain, EU)
    NESTOR SZERMAN (Madrid, Spain, EU)
  • Chimera Award 2026 - CARLOS ALONSO RONCERO (Valladolid, Spain, EU)
    CARLOS ALONSO RONCERO (Valladolid, Spain, EU)
  • Chimera Award 2026 - CARLOS ALONSO RONCERO (Valladolid, Spain, EU)
    CARLOS ALONSO RONCERO (Valladolid, Spain, EU)
  • Chimera Award 2026 - WIM VAN DEN BRINK (Amsterdam,Netherlands, EU)
    WIM VAN DEN BRINK (Amsterdam,Netherlands, EU)
  • Chimera Award 2026 - WIM VAN DEN BRINK (Amsterdam,Netherlands, EU)
    WIM VAN DEN BRINK (Amsterdam,Netherlands, EU)

 

Rovai Scholars Award
  • Rovai Scholars Award - MARTIN KABERG (Stockholm, Sweden, EU)
    MARTIN KABERG (Stockholm, Sweden, EU)
  • Rovai Scholars Award - MARKUS THUNBERG (Stockholm, Sweden, EU)
    MARKUS THUNBERG (Stockholm, Sweden, EU)

 

Dinner
  • EUROPAD 2026 - Bucarest dinner
  • EUROPAD 2026 - Bucarest dinner
  • EUROPAD 2026 - Bucarest dinner
  • EUROPAD 2026 - Bucarest dinner
  • EUROPAD 2026 - Bucarest dinner
  • EUROPAD 2026 - Bucarest dinner